Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Two distinct cell lines derived from a human osteosarcoma.

A Kawai1, T Ozaki, S Ikeda

  • 1Department of Orthopaedic Surgery, Cancer Institute, Okayama University Medical School, Japan.

Journal of Cancer Research and Clinical Oncology
|January 1, 1989
PubMed
Summary

Researchers developed two human osteosarcoma cell lines (O9N2 and HuO9) from tumors in mice. The HuO9 cell line showed increased c-myc oncogene amplification, influencing growth and morphology.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Landscape of ultra-rare sarcomas: a nationwide study for epidemiology and prognosis.

ESMO open·2025
Same author

Translocation in bone and soft tissue sarcomas: a comprehensive epidemiological investigation.

ESMO open·2024
Same author

The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology.

ESMO open·2024
Same author

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Area of Science:

  • Oncology
  • Cell Biology
  • Genetics

Background:

  • Osteosarcoma is a primary bone cancer with limited treatment options.
  • Understanding the genetic alterations driving osteosarcoma progression is crucial for developing targeted therapies.

Purpose of the Study:

  • To establish and characterize human osteosarcoma cell lines derived from a xenograft model.
  • To investigate the role of specific oncogenes and tumor suppressor genes in osteosarcoma cell behavior.

Main Methods:

  • Establishment of two distinct cell lines (O9N2 and HuO9) from human osteosarcoma xenografts in nude mice.
  • Analysis of cell morphology, growth characteristics, and alkaline phosphatase activity.
  • Molecular analysis including oncogene amplification (c-myc) and tumor suppressor gene deletion (Rb gene).

Related Experiment Videos

Main Results:

  • Both cell lines exhibited 1,25(OH)2D3-responsive alkaline phosphatase activity and formed tumors similar to the original osteosarcoma.
  • HuO9 cells displayed spindle shapes, a higher growth rate, and saturation density compared to the polygonal O9N2 cells.
  • HuO9 cells showed 4- to 8-fold amplification of the c-myc oncogene, while O9N2 cells did not.
  • Both cell lines possessed a homozygous deletion in the Rb gene.

Conclusions:

  • The c-myc oncogene appears to play a significant role in controlling the growth and morphology of human osteosarcoma cells.
  • Alterations in the Rb gene are implicated in the pathogenesis of this osteosarcoma.
  • These cell lines provide valuable tools for studying osteosarcoma biology and testing therapeutic strategies.